Author

Ling-Xiang Liu

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Comparative efficacy and safety of protocol-defined 2-year versus indefinite immunotherapy strategies for advanced non-small-cell lung cancer: A systematic review and network meta-analysis

The optimal duration of immune checkpoint inhibitor (ICI)-based therapy for advanced non-small-cell lung cancer (NSCLC) remains uncertain. To compare first-line ICI-based regimens with a protocol-defined maximum treatment duration of approximately 2 years versus indefinite treatment. Systematic review...

Jia-Mei Yu, Qing Ling, Yi Jiao et al. · Therapeutic Advances in Medi... · 0 citations

Review Oct 2026

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

BACKGROUND Ruzaltatug rezetecan is a novel HER3-directed antibody-drug conjugate that has shown promising antitumour activity and manageable safety in pretreated EGFR-.mutated non-small-cell lung cancer (NSCLC) in a phase 1 trial. We aimed to compare the efficacy and safety of ruzaltatug rezetecan with chemotherapy in...

Chong-Rui Xu, Yan Zhang, G. Lin et al. · The Lancet · 1 citation